Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2026 08:00 ET | Source: ConSynance Therapeutics

ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome

First patient dosed in FPWR-supported Phase 2a trial of CSTI-500 for hyperphagia and neurobehavioral symptoms in PWS.
July 24, 2024 10:00 ET | Source: ConSynance Therapeutics

ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome

FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.